A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
复制标题
DOI：
10.1007/s00280-010-1478-7
复制
发表时间：
2011-08
影响因子：
3
通讯作者：
Fuchs, Charles S.
中科院分区：
文献类型：
--
作者：
Kulke, Matthew H.;Chan, Jennifer A.;Meyerhardt, Jeffrey A.;Zhu, Andrew X.;Abrams, Thomas A.;Blaszkowsky, Lawrence S.;Regan, Eileen;Sidor, Carolyn;Fuchs, Charles S.
血管生成抑制已成为神经内分泌肿瘤的一种潜在的有前途的治疗策略。2-甲氧基雌二醇（2ME2; Panzem®）是雌二醇的天然衍生物，在动物模型中具有抗血管生成活性。我们在晚期类癌患者中进行了一项前瞻性II期研究，将2 ME 2与贝伐珠单抗联合给药。31例晚期类癌患者接受了2ME 2治疗，口服剂量为1，000 mg，每日4次。患者还接受贝伐珠单抗5 mg/kg静脉注射，每2周一次。观察患者的毒性、肿瘤反应和存活率。2ME 2和贝伐单抗的组合相对容易耐受，并且与这两种药物的预期毒性相关。未观察到经证实的放射学缓解（根据RECIST）。然而，68%的放射学可评估患者经历了至少一定程度的肿瘤缩小，中位无进展生存期（PFS）为11.3个月。2ME 2和贝伐单抗可以安全地用于晚期类癌患者。虽然该方案未观察到主要肿瘤消退，但令人鼓舞的中位无进展生存时间表明该方案具有一定程度的抗肿瘤活性，并支持进一步研究该疾病中的血管生成抑制剂。
Angiogenesis inhibition has emerged as a potentially promising treatment strategy for neuroendocrine tumors. 2-Methoxyestradiol (2ME2; Panzem®) is a natural derivative of estradiol with demonstrated anti-angiogenic activity in animal models. We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors. Thirty-one patients with advanced carcinoid tumors were treated with 2ME2, administered orally at a dose of 1,000 mg four times daily. Patients also received bevacizumab 5 mg/kg intravenously every 2 weeks. Patients were observed for evidence of toxicity, tumor response, and survival. The combination of 2ME2 and bevacizumab was relatively easily tolerated and was associated with anticipated toxicities for these two agents. No confirmed radiologic responses (by RECIST) were observed. However, 68% of the radiologically evaluable patients experienced at least some degree of tumor reduction, and the median progression-free survival (PFS) time was 11.3 months. 2ME2 and bevacizumab can be safely administered to patients with advanced carcinoid tumors. While major tumor regression was not observed with this regimen, the encouraging median progression-free survival time suggests that this regimen has some degree of anti-tumor activity and supports the further investigation of angiogenesis inhibitors in this disease.
登录
查看更多内容
影响因子：
4.7
作者：
Matei, Daniela;Schilder, Jeanne;Sidor, Carolyn
通讯作者：
Sidor, Carolyn
影响因子：
3.6
作者：
Hughes, RA;Harris, T;Stewart, AG
通讯作者：
Stewart, AG
影响因子：
158.5
作者：
MOERTEL, CG;LEFKOPOULO, M;KLAASSEN, D
通讯作者：
KLAASSEN, D
影响因子：
3.6
作者：
Dahut, WL;Lakhani, NJ;Figg, WD
通讯作者：
Figg, WD
影响因子：
45.3
作者：
Feldman, Darren R.;Baum, Michael S.;Motzer, Robert J.
通讯作者：
Motzer, Robert J.